Droperidol and QTc Interval Changes in ED Patients
NCT06726811
Recruiting
Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: CHRISTUS Spohn Hospital Corpus Christi-Shoreline, Corpus Christi, Texas
Conditions: Emergency Department Patient, QTc Intervals Changes
Register for Updates
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
NCT04080804
Recruiting
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates
The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease
NCT04505865
Recruiting
This study aims to evaluate the effect of 8 weeks of a stress reduction intervention on atherosclerotic plaque inflammation in adults with stable coronary artery disease, as quantified by positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in individuals with increased psychosocial stress.
Gender:
ALL
Ages:
Between 45 years and 65 years
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Atherosclerosis, Stress, Inflammation
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Children's of Alabama, Birmingham, Alabama +98 locations
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Superficial Cervical Plexus Block for Improved Outcomes in Pediatric Otolaryngologic Surgery
NCT06023329
Recruiting
Literature on the use of superficial cervical plexus blocks for ear surgery is sparse in general, and almost non-existent in the pediatric population. Overall, literature review supports the safety of performance of this block but there is minimal published literature on its utility despite anecdotal evidence of benefit. This study, especially its prospective randomized nature will allow for expansion of the evidence for or against addition of this block to the care of pediatric patients undergo... Read More
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
12/11/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Otolaryngologic Surgery
Register for Updates
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
NCT06529094
Recruiting
Spinal cord injury (SCI) is a permanent condition affecting every aspect of life including health, daily activities, and participation and quality of life. Persons with SCI are at high risk of pressure injury (PrI) throughout their lives due to loss of sensation, nerve damage and immobility. PrIs are local areas of damage to the skin and underlying soft tissue caused by pressure and shear commonly located over bony prominences. While most PrIs are hospital- or nursing home-acquired, in people wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California +4 locations
Conditions: Spinal Cord Injury, Pressure Injury
Register for Updates
Dose Escalation and Expansion Study of HM16390 in Advanced or Metastatic Solid Tumors
NCT06724016
Recruiting
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into at each dose level. After a comprehensive review of available data from bo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
Exosome Cargo from Preeclampsia Patients
NCT04154332
Recruiting
Although extensively studied, the cause of preeclampsia remains uncertain other than it is thought that the placenta plays a critical role in the development of preeclampsia. Recent data revealed that exosomes released from the placenta could cause preeclampsia by transporting specific cargo responsible for the pathophysiological changes associated with the systemic disease. By isolating these exosomes from maternal blood and placental tissue in patients diagnosed with preeclampsia and studying... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
12/11/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Preeclampsia
Register for Updates
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT04812366
Recruiting
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: University of California Davis, Sacramento, California +8 locations
Conditions: Prostate Cancer
Register for Updates
Predicting Outcomes in Hypoglossal Nerve Stimulation Therapy With Stimulated Upper Airway Mechanics
NCT05429983
Recruiting
Obstructive sleep apnea (OSA) is a highly prevalent disease resulting from dynamic upper airway collapse during sleep. Continuous positive airway pressure (CPAP) is highly efficacious but high rates of non-adherence to CPAP leaves large number of OSA patients at risk for cardiometabolic sequelae. Inspire™ is an FDA-approved hypoglossal nerve stimulation device (HGNS) used in select patients with OSA who are intolerant of CPAP. The device consists of an implanted impulse generator with a stimulat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Sleep Apnea, Obstructive
Register for Updates
Oxytocin Effects on Bone in Children with Autism Spectrum Disorder
NCT05754073
Recruiting
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin on bone health in children with autism spectrum disorder, ages 6-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (30 IU, 2 times daily) for 12 months in the double-blind phase, followed by a 6-month open label phase during which all study subjects will receive intranasal oxytocin (30 IU, 2 times daily). Study visits include screening to determine eligibility, fol... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
12/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Autism Spectrum Disorder, Bone Health
Register for Updates
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
NCT06049082
Recruiting
The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency (AATD) via nebulization. This study is designed to evaluate safety and pharmacodynamics of KB408 in adults with AATD with a PI\*ZZ or PI\*ZNull genotype. Three planned dose levels of KB408 will be evaluated in single dose escalation cohorts. Subjects tak... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/11/2024
Locations: Medical University of South Carolina, Charleston, South Carolina +1 locations
Conditions: Alpha 1-Antitrypsin Deficiency
Register for Updates